Semaglutide directly improved heart cell contractility and reduced dangerous calcium leaks in human heart tissue from patients with heart failure, acting through the GLP-1 receptor.
Normalized to non-failingSemaglutide reduced late sodium current in diseased heart cells to levels seen in healthy hearts
What the researchers found
Semaglutide demonstrated direct cardioprotective effects on isolated human cardiomyocytes from three groups: non-failing hearts, aortic stenosis with HFpEF-like phenotype, and end-stage HFrEF.
Key findings included: reduction of late sodium current (INa) in diseased cardiomyocytes to levels comparable with non-failing hearts; decreased diastolic sarcoplasmic reticulum (SR) calcium leak; improved systolic calcium transients and contractility in both AS and HFrEF tissue; and dose-dependent improvement of myocardial contractility in multicellular preparations. These effects were mediated through GLP-1 receptor agonism (blocked by exendin 9-39) and were comparable to CaMKII inhibition.
Why it matters
Clinical trials have shown semaglutide reduces cardiovascular events, but no one knew exactly why at the cellular level. This study provides the first direct evidence that semaglutide acts on human heart cells themselves — not just indirectly through weight loss or blood sugar control — fixing the specific ion-handling defects that drive heart failure progression.
How the study worked
Human left ventricular cardiomyocytes were isolated from non-failing donor hearts, patients with aortic stenosis (HFpEF-like), and end-stage HFrEF patients. Researchers measured late sodium current, SR calcium leak, calcium transients, and contractility with and without semaglutide treatment. CaMKII inhibitor peptide and GLP-1 receptor antagonist were used to confirm the signaling pathway.
What this study cannot tell us
This was an ex vivo study on isolated heart cells and tissue strips, which may not fully replicate the complexity of semaglutide's effects in a living patient. The concentration of semaglutide used in the lab may differ from what reaches the heart during clinical dosing. Sample sizes for each patient group were not specified in the abstract. Long-term effects on cardiac remodeling cannot be assessed in this experimental setting.
How to read the evidence
This is a rigorous translational study using actual human heart tissue from multiple patient populations with appropriate controls and pathway verification. However, it remains ex vivo (outside the body) evidence that needs clinical confirmation.
When this study was published
Published in 2025 in the European Journal of Heart Failure, this is a very recent mechanistic study adding important context to ongoing clinical trials of semaglutide in heart failure.
The bigger picture
This study shifts the understanding of how GLP-1 receptor agonists protect the heart. Rather than benefits being entirely secondary to metabolic improvements, semaglutide appears to have direct cardiac effects at the cellular level. This mechanistic insight could support expanded use of semaglutide in heart failure patients regardless of diabetes or obesity status.
Questions still open
- Do the semaglutide concentrations used in this study reflect the drug levels that actually reach the human heart during standard clinical dosing?
- Could semaglutide's direct cardiac effects be additive with its metabolic benefits to provide even greater cardiovascular protection?
- Should semaglutide be considered as a heart failure therapy independent of its metabolic indications?
Common questions
Does semaglutide help the heart directly or just through weight loss?
What is CaMKII and why does it matter?
Read the original research
Cardioprotective effects of semaglutide on isolated human ventricular myocardium.
European journal of heart failure, 27(7), 1315-1325
Citation
Krammer, Thomas; Baier, Maria J; Hegner, Philipp; Zschiedrich, Tilman; Lukas, David; Wolf, Matthias; Le Phu, Christian; Lutz, Vanessa; Evert, Katja; Kozakov, Kostiantyn; Li, Jing; Holzamer, Andreas; Maier, Lars S; Provaznik, Zdenek; Bers, Donald M; Wagner, Stefan; Mustroph, Julian. (2025). Cardioprotective effects of semaglutide on isolated human ventricular myocardium.. European journal of heart failure, 27(7), 1315-1325. https://doi.org/10.1002/ejhf.3644